aldafermin
ngm biopharmaceuticals,spdr s&p biotech,ishares biotechnology
['$ibb', '$ngm', '$xbi']
$ngm ngm bio presents phase 2 data on aldafermin for diarrhea-predominant ibs-d and bam at digestive disease week 2023. -d more info: $xbi $ibb $xph $pph 
BioPharma/Biotech Intel.  Daily $XBI $XPH Market Movers

Database: https://t.co/IBOqbSoYuc
Clinical trial tools: https://t.co/A77u9Q84Dc  http://globalclinicalt